[Featured Stock] Genome Analysis Technology Platform Company Selemix Hits Upper Limit

Genome analysis technology platform company Selemix is hitting the upper price limit.

As of 9:06 AM on the 12th, Selemix is trading at 5,200 KRW on the KOSDAQ market, up 1,200 KRW (30%) from the previous trading day.

Selemix has developed the next-generation cloning technology MSSIC and three productization technologies, conducting businesses in Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions.

It supplies products to major institutions in the bio industry such as hospitals, contract testing organizations, pharmaceutical companies, seed companies, and research institutes.

It is used as an essential material to create value in a wide range of fields including diagnostics, new drug development, seed development, synthetic biology, microbiome, and academic research.